Suppr超能文献

单克隆抗体作为放射性药物的可逆平衡载体。

Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals.

作者信息

Goodwin D A, Meares C F, David G F, McTigue M, McCall M J, Frincke J M, Stone M R, Bartholomew R M, Leung J P

出版信息

Int J Rad Appl Instrum B. 1986;13(4):383-91. doi: 10.1016/0883-2897(86)90015-2.

Abstract

We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 micrograms MoAb CHA255 Kb = 4 X 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 micrograms; to days with 100 micrograms. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3% per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50% within 3 h or i.v. injection of a "flushing" dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.

摘要

我们制备了具有特异性结合金属螯合物(如铟 - 111标记的苄基乙二胺四乙酸)能力的单克隆抗体(MoAbs)。将1、10、50和100微克单克隆抗体CHA255(解离常数Kb = 4×10⁹)与铟 - 111标记的二乙三胺五乙酸苄酯(BLEDTA II)、四乙五胺六乙酸苄酯(BLEDTA IV)以及苄基乙二胺四乙酸络合,然后静脉注射到患有KHJJ肿瘤的Balb/c小鼠体内。通过全身计数得出,这三种化合物的生物半衰期都发生了显著变化;10微克时从几分钟变为几小时;100微克时变为几天。随着单克隆抗体用量增加,24小时时肿瘤摄取量增加了50倍,但对于人类而言,使用相当于7毫克的量可获得令人满意的肿瘤浓度(每克3%)和肿瘤/血液比率(1.8:1)。静脉注射未标记的铟苄基乙二胺四乙酸的“冲洗”剂量后3小时内,血液水平和全身活性降低30 - 50%,肿瘤/血液比率提高到50:1。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验